Clinical trials: Intravenous Administration
Huntington Disease
Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients.
Cellavita-HD is a stem-cell therapy for Huntington's Disease. Open label, single treatment, extension study for long-term safety and efficacy evaluation of Cellavita-HD intravenous administration in Huntington's disease patients…
- Trial name
- ADORE-EXT (NCT04219241)
- Testing
- Cellavita-HD
- Where
- Brazil
- Volunteers
- 35 people
- Sponsor
- Azidus Brasil
Unspecified Adult Solid Tumor, Protocol Specific
VNP20009 in Treating Patients With Advanced Solid Tumors
RATIONALE: Biological therapies such as VNP20009 use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00006254
- Testing
- salmonella VNP20009
- Where
- 2 sites in United States
- Sponsor
- Vion Pharmaceuticals
Schizophrenia
Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242
This study involves evaluating the occupancy of ATI-9242 at steady state at three different dose levels on D2 receptors in the brain using [18F] Fallypride PET in up to three cohorts of subjects.
- Trial name
- NCT02824666
- Testing
- ATI-9242, [18F]Fallypride Imaging
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Braeburn Pharmaceuticals
Postoperative Gastrointestinal Dysfunction
A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery
The main aim of this study is to check for side effects from TAK-954 and whether it speeds up the recovery of gastrointestinal function after small-bowel or large-bowel resection surgery.
- Trial name
- NCT03827655
- Testing
- TAK-954
- Where
- 25 sites in United States, Germany
- Volunteers
- 209 people
- Sponsor
- Takeda
Multiple Myeloma, Multiple Myeloma in Relapse
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, B cell lymphoma or plasma cell leukemia patients when given by intravenous infusion at various doses.
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Mantle Cell Lymphoma in Relapse, Diffuse Large B Cell Lymphoma in Relapse
- Trial name
- NCT01435720
- Testing
- SNS01-T
- Where
- 7 sites in United States, South Africa
- Volunteers
- 15 people
- Sponsor
- Senesco Technologies, Inc.
Healthy Volunteers
A Phase 1 Study to Evaluate Pharmacokinetics, Safety and Tolerability of ZL-1503 in Healthy Volunteers
This is a phase 1, single dose, randomized, open-label, parallel-group study to evaluate the pharmacokinetics (PK), safety, tolerability and immunogenicity of ZL-1503 and to explore its PD biomarkers following a single…
- Trial name
- NCT07658482
- Testing
- ZL-1503
- Where
- New Zealand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Osteoporosis, Spinal Fractures
Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis
The purpose of this study is to evaluate the safety of intravenous infusion of fucosylated autologous bone marrow cells as a new therapy in patients with established osteoporosis by a prospective, single-center, open…
- Trial name
- CSM/OP/2011 (NCT02566655)
- Testing
- Fucosylated MSC for Osteoporosis
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Red de Terapia Celular
Healthy Volunteer
Safety, Tolerability, and Pharmacokinetics of DD-S052P in Healthy Volunteers
This is a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study designed to evaluate the safety, tolerability, and pharmacokinetics of DD-S052P in healthy adult volunteers.
- Trial name
- NCT07347223
- Testing
- DD-S052P
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- HLB Science
Colorectal Cancer, Ovarian Cancer
A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer
This exploratory, open label study will assess the the dose-effect relationship, efficacy and safety of RO5323441 in patients with metastatic treatment-refractory colorectal or ovarian cancer.
- Trial name
- NCT01148758
- Testing
- RO5323441
- Where
- 3 sites in Belgium, Spain and 1 more
- Volunteers
- 7 people
- Sponsor
- Hoffmann-La Roche
Healthy
A Study of Ramucirumab (LY3009806) in Healthy Participants
This study evaluates a new formulation of ramucirumab, a drug approved for several types of cancer. In this study of healthy participants, a small amount of ramucirumab will be given by injection either into a vein or just under…
- Trial name
- NCT04495478
- Testing
- Ramucirumab - IV, Ramucirumab - SC
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Symptomatic Decompensated Congestive Heart Failure, Congestive Heart Failure in Acute Coronary Syndrome
A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure.
The purpose of this study is to compare the hemodynamic (blood flow) and clinical effects of the study drug, Natrecor (nesiritide, a recombinant form of the natural human peptide normally secreted by the heart in response to…
- Trial name
- NCT00270374
- Testing
- nesiritide
- Volunteers
- 498 people
- Sponsor
- Scios, Inc.
Acute Exacerbation of Remitting Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)
Patients with an acute exacerbation of Relapsing-Remitting Multiple Sclerosis or with Clinically Isolated Syndrome receive either one single infusion of Nanocort or three daily infusions of SoluMedrol.
- Trial name
- NCT01039103
- Testing
- PEG-liposomal prednisolone sodium phosphate, Methylprednisolone
- Where
- 8 sites in Belgium, Germany and 1 more
- Volunteers
- 15 people
- Sponsor
- Lakefront Biotherapeutics NV
Chronic Kidney Disease, Secondary Hyperparathyroidism
Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous
The purpose of this study is to assess health-related Quality of Life (QoL) changes in participants with chronic kidney disease (CKD) and secondary hyperparathyroidism (sHPT) undergoing hemodialysis and receiving paricalcitol…
- Trial name
- QUALITIZE (NCT01368042)
- Where
- 11 sites in Greece
- Volunteers
- 265 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
OIC
TD-1211 IV/Oral Mass Balance Study
The purpose of this study is to determine TD-1211 is processed by the body.
- Trial name
- NCT01702194
- Testing
- TD-1211 IV [C14], TD-1211 PO [C14]
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Glycyx Therapeutics
Metastatic Non-small Cell Lung Cancer
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
This study is to assess the pharmacokinetics (PK) and safety of SC pembrolizumab formulated with berahyaluronidase alfa (MK-3475A) versus (vs) intravenous (IV) pembrolizumab (MK-3475), administered with chemotherapy in first line…
- Trial name
- NCT05722015
- Testing
- Pembrolizumab Formulated with Berahyaluronidase Alfa, Pemetrexed, Cisplatin
- Where
- 110 sites in United States, Argentina and 14 more
- Volunteers
- 377 people
- Sponsor
- Merck Sharp & Dohme LLC
Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
The primary objective of this study is to investigate the efficacy, safety, and tolerability of RV 001 (teprotumumab), a fully human anti-IGF1R antibody, administered q3W for 6 months, in comparison to placebo, in the treatment…
- Trial name
- NCT01868997
- Testing
- teprotumumab, normal saline
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 88 people
- Sponsor
- Amgen
Rheumatoid Arthritis
A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis
This is a phase 3 study to compare efficacy and safety of CT-P47 and RoActemra in patients with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT05489224
- Testing
- CT-P47, EU-approved RoActemra
- Where
- Poland
- Volunteers
- 471 people
- Sponsor
- Celltrion
Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia
Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria
Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative…
- Trial name
- NCT07512596
- Testing
- TQD3524, Meropenem for injection, Colistimethate Sodium for Injection
- Where
- 27 sites in China
- Volunteers
- 48 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Efficacy and Safety Evaluation of Refralon®, Concentrate for Solution for Intravenous Injection in Patients With Paroxysmal and Persistent Atrial Fibrillation and Flutter
The goal of this retrospective registry is to evaluate the efficacy and safety of Refralon®, concentrate for solution for intravenous injection, as chemical cardioversion in patients with paroxysmal and persistent atrial…
- Conditions
- Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Atrial Flutter
- Trial name
- NCT05773170
- Testing
- Refralon
- Where
- 33 sites in Russia
- Volunteers
- 1,147 people
- Sponsor
- R-Pharm
Anemia
A Study of Mircera for the Treatment of Anemia in Dialysis Patients
This study will assess the efficacy and safety of Mircera given intravenously in the treatment of renal anemia in chronic kidney disease patients on dialysis who are not currently receiving epoetin or any other erythropoietic…
- Trial name
- NCT00077597
- Testing
- epoetin, methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 59 sites in United States, Brazil and 11 more
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.